Pacific Biosciences of California Inc (PACB)

[Paulieme]

October 27, 2014 17:02 ET |New DNA Sequencing Facility Established in China Based on PacBio's SMRT Sequencing Platform
MENLO PARK, Calif. and TIANJIN, China, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc., (Nasdaq:PACB) provider of the PacBio® RS II DNA Sequencing System, and Suqian Lakeside Pangu Gene Company (SLPC) announced that SLPC has established a new genomics facility with 1,500 square meters of laboratory space in the Tianjin Dong Li Lake Technology Park, dedicated to using PacBio Single Molecule, Real-Time (SMRT®) Sequencing as the major sequencing platform for its translational medicine research projects.

"Our goal is to become an innovative high-tech enterprise," stated founder and CEO of SLPC, Dr. Zhang Yaozhou. "I believe that PacBio's platform provides the most complete and accurate sequencing data, and we are committed to applying this technology toward the improvement of human health."

SLPC purchased four PacBio RS II Sequencing Systems earlier this year and recently installed them at their newly dedicated facility. The company ultimately intends to focus on applications such as molecular-based approaches for early diagnosis of cancers, disease recurrence control and drug efficacy evaluation.

Ram Laxman, Ph.D., President & General Manager, Asia Pacific for Pacific Biosciences commented: "SLPC's investment in the PacBio RS II systems for human and other large genome sequencing follows a growing trend of researchers adopting the SMRT Sequencing technology to generate highly accurate complete genomes."

http://globenewswire.com/news-release/2014/10/27/676936/10104682/en/New-DNA-Sequencing-Facility-Established-in-China-Based-on-PacBio-s-SMRT-Sequencing-Platform.html?f=22&fvtc=7